Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.
Breast Cancer Res Treat
; 157(1): 145-56, 2016 05.
Article
em En
| MEDLINE
| ID: mdl-27107569
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Receptor ErbB-2
/
Trastuzumab
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Breast Cancer Res Treat
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Estados Unidos